Cargando…

N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy

AIM: To examine the relationship between plasma levels of N-terminal-proB type natriuretic peptide (NT-proBNP) and various echocardiographic and hemodynamic parameters in patients with mitral stenosis undergoing percutaneous transvenous mitral commissurotomy (PTMC). MATERIALS AND METHODS: The study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranganayakulu, K.P., Rajasekhar, D., Vanajakshamma, V., Santosh Kumar, C., Vasudeva Chetty, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803762/
https://www.ncbi.nlm.nih.gov/pubmed/27053897
http://dx.doi.org/10.1016/j.jsha.2015.07.002
_version_ 1782422901644853248
author Ranganayakulu, K.P.
Rajasekhar, D.
Vanajakshamma, V.
Santosh Kumar, C.
Vasudeva Chetty, P.
author_facet Ranganayakulu, K.P.
Rajasekhar, D.
Vanajakshamma, V.
Santosh Kumar, C.
Vasudeva Chetty, P.
author_sort Ranganayakulu, K.P.
collection PubMed
description AIM: To examine the relationship between plasma levels of N-terminal-proB type natriuretic peptide (NT-proBNP) and various echocardiographic and hemodynamic parameters in patients with mitral stenosis undergoing percutaneous transvenous mitral commissurotomy (PTMC). MATERIALS AND METHODS: The study population consisted of 100 patients with rheumatic mitral stenosis who underwent PTMC. NT-proBNP levels in these patients were measured before PTMC and 48 hours after PTMC. These levels were then correlated with various echocardiographic and hemodynamic parameters measured before and after PTMC. RESULTS: Eighty-one percent of the study population were women, and the most common presenting symptom was dyspnea which was present in 94% of the patients. Dyspnea New York Heart Association class correlated significantly with baseline NT-proBNP levels (r = 0.63; p < 0.01). The plasma NT-proBNP levels in these patients increased as echocardiogram signs of left atrial enlargement and right ventricular hypertrophy developed (r = 0.59, p < 0.01). Patients in atrial fibrillation had significantly higher NT-proBNP levels than patients in sinus rhythm. Baseline NT-proBNP levels correlated significantly with left atrial volume (r = 0.38; p < 0.01), left atrial volume index (r = 0.45; p < 0.01), systolic pulmonary artery pressures (r = 0.42; p < 0.01), and mean pulmonary artery pressures (r = 0.41; p < 0.01). All patients who underwent successful PTMC showed a significant decrease in NT-proBNP (decreased from a mean 763.8 pg/mL to 348.6 pg/mL) along with a significant improvement in all echocardiographic and hemodynamic parameters (p < 0.01). The percent change in NT-proBNP correlated significantly with the percent improvement noted with left atrial volume (r = 0.39; p < 0.01), left atrial volume index (r = 0.41; p < 0.01), systolic (r = 0.32, p < 0.01), and mean pulmonary artery pressures (r = 0.31, p < 0.01). CONCLUSIONS: The decrease in NT-proBNP levels following PTMC reflects an improvement in clinical and hemodynamic status; hence, it is reasonable to suggest that NT-proBNP is helpful in evaluating the response to PTMC.
format Online
Article
Text
id pubmed-4803762
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48037622016-04-06 N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy Ranganayakulu, K.P. Rajasekhar, D. Vanajakshamma, V. Santosh Kumar, C. Vasudeva Chetty, P. J Saudi Heart Assoc Full Length Article AIM: To examine the relationship between plasma levels of N-terminal-proB type natriuretic peptide (NT-proBNP) and various echocardiographic and hemodynamic parameters in patients with mitral stenosis undergoing percutaneous transvenous mitral commissurotomy (PTMC). MATERIALS AND METHODS: The study population consisted of 100 patients with rheumatic mitral stenosis who underwent PTMC. NT-proBNP levels in these patients were measured before PTMC and 48 hours after PTMC. These levels were then correlated with various echocardiographic and hemodynamic parameters measured before and after PTMC. RESULTS: Eighty-one percent of the study population were women, and the most common presenting symptom was dyspnea which was present in 94% of the patients. Dyspnea New York Heart Association class correlated significantly with baseline NT-proBNP levels (r = 0.63; p < 0.01). The plasma NT-proBNP levels in these patients increased as echocardiogram signs of left atrial enlargement and right ventricular hypertrophy developed (r = 0.59, p < 0.01). Patients in atrial fibrillation had significantly higher NT-proBNP levels than patients in sinus rhythm. Baseline NT-proBNP levels correlated significantly with left atrial volume (r = 0.38; p < 0.01), left atrial volume index (r = 0.45; p < 0.01), systolic pulmonary artery pressures (r = 0.42; p < 0.01), and mean pulmonary artery pressures (r = 0.41; p < 0.01). All patients who underwent successful PTMC showed a significant decrease in NT-proBNP (decreased from a mean 763.8 pg/mL to 348.6 pg/mL) along with a significant improvement in all echocardiographic and hemodynamic parameters (p < 0.01). The percent change in NT-proBNP correlated significantly with the percent improvement noted with left atrial volume (r = 0.39; p < 0.01), left atrial volume index (r = 0.41; p < 0.01), systolic (r = 0.32, p < 0.01), and mean pulmonary artery pressures (r = 0.31, p < 0.01). CONCLUSIONS: The decrease in NT-proBNP levels following PTMC reflects an improvement in clinical and hemodynamic status; hence, it is reasonable to suggest that NT-proBNP is helpful in evaluating the response to PTMC. Elsevier 2016-04 2015-07-18 /pmc/articles/PMC4803762/ /pubmed/27053897 http://dx.doi.org/10.1016/j.jsha.2015.07.002 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Ranganayakulu, K.P.
Rajasekhar, D.
Vanajakshamma, V.
Santosh Kumar, C.
Vasudeva Chetty, P.
N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
title N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
title_full N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
title_fullStr N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
title_full_unstemmed N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
title_short N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
title_sort n-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803762/
https://www.ncbi.nlm.nih.gov/pubmed/27053897
http://dx.doi.org/10.1016/j.jsha.2015.07.002
work_keys_str_mv AT ranganayakulukp nterminalprobrainnatriureticpeptideasurrogatebiomarkerofcombinedclinicalandhemodynamicoutcomesfollowingpercutaneoustransvenousmitralcommissurotomy
AT rajasekhard nterminalprobrainnatriureticpeptideasurrogatebiomarkerofcombinedclinicalandhemodynamicoutcomesfollowingpercutaneoustransvenousmitralcommissurotomy
AT vanajakshammav nterminalprobrainnatriureticpeptideasurrogatebiomarkerofcombinedclinicalandhemodynamicoutcomesfollowingpercutaneoustransvenousmitralcommissurotomy
AT santoshkumarc nterminalprobrainnatriureticpeptideasurrogatebiomarkerofcombinedclinicalandhemodynamicoutcomesfollowingpercutaneoustransvenousmitralcommissurotomy
AT vasudevachettyp nterminalprobrainnatriureticpeptideasurrogatebiomarkerofcombinedclinicalandhemodynamicoutcomesfollowingpercutaneoustransvenousmitralcommissurotomy